{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:15Z","timestamp":1753891875710,"version":"3.41.2"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005315","name":"Natural Science Foundation of Ningbo Municipality","doi-asserted-by":"publisher","award":["2021J281"],"award-info":[{"award-number":["2021J281"]}],"id":[{"id":"10.13039\/501100005315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Recurrence of urothelial carcinoma in a patient with solitary kidney is always a clinical challenge. In the immune checkpoint inhibitor era, neoadjuvant immunotherapy in combination with the Yang\u2013Monti technique might be a good option for the patient with a high-risk tumor when kidney-sparing surgery for renal function preservation is desired. We report the case of a 74-year-old man with solitary kidney who was diagnosed with recurrence of urothelial carcinoma in the right ureter. He was initially deemed unfit for segmental resection of the ureter. Neoadjuvant immunotherapy with tislelizumab was performed in this patient with a partial response to urothelial carcinoma. He underwent segmental resection of the ureter with negative margins, and the ureteral defect was bridged by modified ileal replacement, which is the Yang\u2013Monti technique. This patient has remained disease-free with adequate kidney function for longer than 18 months.<\/jats:p>","DOI":"10.3389\/fonc.2022.889028","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T05:35:56Z","timestamp":1658986556000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: A case of neoadjuvant immunotherapy in combination with the Yang\u2013Monti technique for the treatment of ureteral carcinoma after radical cystectomy and left radical nephroureterectomy"],"prefix":"10.3389","volume":"12","author":[{"given":"Tielin","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harris","family":"Haleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.eururo.2012.05.008","article-title":"Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature","volume":"62","author":"Soukup","year":"2012","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.07.014","article-title":"Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: A systematic review by the EAU non-muscle invasive bladder cancer guidelines panel","volume":"70","author":"Seisen","year":"2016","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(96)00503-1","article-title":"New techniques for construction of efferent conduits based on the mitrofanoff principle","volume":"49","author":"Monti","year":"1997","journal-title":"Urology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35625-2","article-title":"Yang needle tunneling technique in creating antireflux and continent mechanisms","volume":"150","author":"Yang","year":"1993","journal-title":"J Urol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"European urology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14681","article-title":"Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma","volume":"112","author":"Ye","year":"2021","journal-title":"Cancer Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2520","article-title":"DNA Damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma","volume":"23","author":"Teo","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14222","article-title":"Intestinal interposition for complex ureteral reconstruction: A comprehensive review","volume":"27","author":"Xiong","year":"2020","journal-title":"Int J Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3109\/21681805.2014.882980","article-title":"Yang-monti ileal ureter reconstruction","volume":"49","author":"Maigaard","year":"2015","journal-title":"Scand J Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2020.09.061","article-title":"Long-term outcome of yang-monti ileal replacement of the ureter: A technique suitable for mild, moderate loss of kidney function and solitary kidney","volume":"152","author":"Ali-El-Dein","year":"2021","journal-title":"Urology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.889028\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T05:36:00Z","timestamp":1658986560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.889028\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":12,"alternative-id":["10.3389\/fonc.2022.889028"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.889028","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"article-number":"889028"}}